




PHARMACEUTICAL 2022

Evofem Biosciences Inc.
Rank 452 of 466





PHARMACEUTICAL 2022

Evofem Biosciences Inc.
Rank 452 of 466

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Evofem Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 308% points.

The company's Economic Capital Ratio, given in the ranking table, is -405%, being 483% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	30,140
Cost of Goods Sold	4,055
Intangible Assets	0
Liabilities, Current	137,663
Liabilities, Non-Current	4,424
Other Assets	6,598
Other Compr. Net Income	5,089
Other Expenses	113,169
Other Liabilities	0
Other Net Income	-38,374
Other Revenues	8,244
Property and Equipment	5,774
Research and Development	33,129
Selling, General and Administrative Expense	24,709

Output Variable	Value in 1000 USD
Assets	42,512
Liabilities	142,087
Expenses	175,062
Revenues	8,244
Stockholders Equity	-99,575
Net Income	-205,192
Comprehensive Net Income	-202,648
Economic Capital Ratio	-405%